Open Access<p>CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review</p>
Author(s) -
Julia Boyle,
Christopher Stock
Publication year - 2020
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s261424
Subject(s) - hydrocodone , medicine , oxycodone , tramadol , cyp2d6 , opioid , genotyping , methadone , opioid overdose , pharmacology , cyp2b6 , oxymorphone , pharmacogenetics , anesthesia , genotype , (+) naloxone , cyp1a2 , genetics , cytochrome p450 , biology , analgesic , receptor , metabolism , gene
The purpose is to characterize the CYP2D6 genotype and predict the phenotype of decedents of opioid overdose to determine if the ultrarapid (UM) phenotype is over-represented in opioid overdose deaths. CYP2D6 is the enzyme responsible for metabolism of various opioids implicated in overdose. The UM group may be at greater risk for overdose due to the rapid metabolism of hydrocodone, oxycodone, or tramadol to more active/potent metabolites than their peers with (poor) PM, (intermediate) IM, or (extensive) EM metabolic phenotypes.